Ovarian Cancer

E1B Deleted Adenovirus Infection Inhibits Tumor Growth In Vivo

Published in Cancer Weekly, May 15th, 2001

by Deborah W. Heinrich, PhD, staff medical writer - Researchers at Beatson Laboratory in Scotland demonstrated that infection with an E1B 55kDa deleted adenovirus (ONYX-015) inhibited tumor growth in vivo.

I. Ganly and colleagues noted that the ONYX-015 adenovirus induced lysis of cells with p53 mutations. In this study, they used ONYX-015 to infect human ovarian tumor cell lines with known p53 mutations and chemoresistance and reported their results in Gene Therapy.

The parent cell line, A2780, is chemosensitive to cisplatin and expresses wild-type p53. The mutant p53 derivative, A2780/cp70 is cisplatin resistant. Ganly and coworkers...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry